200,000+ products from a single source!
sales@angenechem.com
Home > Other Building Blocks > 100324-81-0
100324-81-0 | 1H-Purine-2,6-dione, 3,7-dihydro-1-[(5R)-5-hydroxyhexyl]-3,7-dimethyl-
CAS No: 100324-81-0 Catalog No: AG0001MI MDL No:MFCD00867573
Product Description
Catalog Number:
AG0001MI
Chemical Name:
1H-Purine-2,6-dione, 3,7-dihydro-1-[(5R)-5-hydroxyhexyl]-3,7-dimethyl-
CAS Number:
100324-81-0
Molecular Formula:
C13H20N4O3
Molecular Weight:
280.3229
MDL Number:
MFCD00867573
IUPAC Name:
1-[(5R)-5-hydroxyhexyl]-3,7-dimethylpurine-2,6-dione
InChI:
InChI=1S/C13H20N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8-9,18H,4-7H2,1-3H3/t9-/m1/s1
InChI Key:
NSMXQKNUPPXBRG-SECBINFHSA-N
SMILES:
C[C@H](CCCCn1c(=O)c2n(C)cnc2n(c1=O)C)O
UNII:
L1F2Q2X956
Properties
Complexity:
390
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
1
Defined Bond Stereocenter Count:
0
Exact Mass:
280.154g/mol
Formal Charge:
0
Heavy Atom Count:
20
Hydrogen Bond Acceptor Count:
4
Hydrogen Bond Donor Count:
1
Isotope Atom Count:
0
Molecular Weight:
280.328g/mol
Monoisotopic Mass:
280.154g/mol
Rotatable Bond Count:
5
Topological Polar Surface Area:
78.7A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
0.7
Literature
| Title | Journal |
|---|---|
| Macrolide antibiotics and survival in patients with acute lung injury. | Chest 20120501 |
| Macrolides for acute lung injury. | Chest 20120501 |
| Amelioration of type 1 diabetes following treatment of non-obese diabetic mice with INGAP and lisofylline. | Journal of diabetes mellitus 20120501 |
| Acute respiratory distress syndrome: pathophysiology and therapeutic options. | Journal of clinical medicine research 20120201 |
| Catenarin Prevents Type 1 Diabetes in Nonobese Diabetic Mice via Inhibition of Leukocyte Migration Involving the MEK6/p38 and MEK7/JNK Pathways. | Evidence-based complementary and alternative medicine : eCAM 20120101 |
| Evidence for activation of inflammatory lipoxygenase pathways in visceral adipose tissue of obese Zucker rats. | American journal of physiology. Endocrinology and metabolism 20110101 |
| Activation of the GLP-1 receptor signalling pathway: a relevant strategy to repair a deficient beta-cell mass. | Experimental diabetes research 20110101 |
| Extrinsic factors involved in the differentiation of stem cells into insulin-producing cells: an overview. | Experimental diabetes research 20110101 |
| Different toll-like receptor stimuli have a profound impact on cytokines required to break tolerance and induce autoimmunity. | PloS one 20110101 |
| Acute respiratory distress syndrome: A clinical review. | Pulmonary circulation 20110101 |
| Current status of immunomodulatory and cellular therapies in preclinical and clinical islet transplantation. | Journal of transplantation 20110101 |
| Targeting ceramide synthesis to reverse insulin resistance. | Diabetes 20101001 |
| Saturated- and n-6 polyunsaturated-fat diets each induce ceramide accumulation in mouse skeletal muscle: reversal and improvement of glucose tolerance by lipid metabolism inhibitors. | Endocrinology 20100901 |
| Bioanalysis of pentoxifylline and related metabolites in plasma samples through LC-MS/MS. | Biomedical chromatography : BMC 20100601 |
| 12-Lipoxygenase Products Reduce Insulin Secretion and {beta}-Cell Viability in Human Islets. | The Journal of clinical endocrinology and metabolism 20100201 |
| Pharmacokinetic interaction between verapamil and methylxanthine derivatives in mice. | Drug metabolism letters 20100101 |
| Pharmacokinetic-pharmacodynamic modeling of methylxanthine derivatives in mice challenged with high-dose lipopolysaccharide. | Pharmacology 20100101 |
| Towards the prevention of acute lung injury: a population based cohort study protocol. | BMC emergency medicine 20100101 |
| Exenatide: a new promising antidiabetic agent. | Indian journal of pharmaceutical sciences 20100101 |
| Bedside quantification of dead-space fraction using routine clinical data in patients with acute lung injury: secondary analysis of two prospective trials. | Critical care (London, England) 20100101 |
| In vivo islet protection by a nuclear import inhibitor in a mouse model of type 1 diabetes. | PloS one 20100101 |
| Immune depletion with cellular mobilization imparts immunoregulation and reverses autoimmune diabetes in nonobese diabetic mice. | Diabetes 20091001 |
| The effects of pentoxifylline on skeletal muscle contractility and neuromuscular transmission during hypoxia. | Indian journal of pharmacology 20091001 |
| Point: steady progress and current challenges in clinical islet transplantation. | Diabetes care 20090801 |
| Pretreatment with R(+)-verapamil significantly reduces mortality and cytokine expression in murine model of septic shock. | International immunopharmacology 20090401 |
| Methyltransferase Set7/9 maintains transcription and euchromatin structure at islet-enriched genes. | Diabetes 20090101 |
| Validation of a high-performance liquid chromatography method for pharmacokinetic evaluation of pentoxifylline and lisofylline in rat serum and tissues. | Acta poloniae pharmaceutica 20090101 |
| Overexpression of thioredoxin in islets transduced by a lentiviral vector prolongs graft survival in autoimmune diabetic NOD mice. | Journal of biomedical science 20090101 |
| Effects of pentoxifylline and its metabolites on platelet aggregation in whole blood from healthy humans. | European journal of pharmacology 20080310 |
| Effects of pentoxifylline on TNF-alpha and lung histopathology in HCL-induced lung injury. | Clinics (Sao Paulo, Brazil) 20080201 |
| Predictive and pathogenetic value of plasma biomarkers for acute kidney injury in patients with acute lung injury. | Critical care medicine 20071201 |
| Dilinoleoyl-phosphatidic acid mediates reduced IRS-1 tyrosine phosphorylation in rat skeletal muscle cells and mouse muscle. | Diabetologia 20070801 |
| Enantioselective reduction of pentoxifylline to lisofylline using whole-cell Lactobacillus kefiri biotransformation. | Biotechnology journal 20070401 |
| Pharmacokinetic modelling of pentoxifylline and lisofylline after oral and intravenous administration in mice. | The Journal of pharmacy and pharmacology 20070401 |
| Pharmacokinetics of intranasal and intratracheal pentoxifylline in rabbits. | Pharmacotherapy 20070201 |
| Prediction of death and prolonged mechanical ventilation in acute lung injury. | Critical care (London, England) 20070101 |
| Enantioselective biotransformation of pentoxifylline into lisofylline using wine yeast biocatalysis. | Acta poloniae pharmaceutica 20070101 |
| Intestinal mucosal dysfunction and infection during remission-induction therapy for acute myeloid leukaemia. | Leukemia 20061201 |
| Interconversion and tissue distribution of pentoxifylline and lisofylline in mice. | Chirality 20060801 |
| Synthesis and biological evaluation of lisofylline (LSF) analogs as a potential treatment for Type 1 diabetes. | Bioorganic & medicinal chemistry letters 20060701 |
| Combined treatment with lisofylline and exendin-4 reverses autoimmune diabetes. | Biochemical and biophysical research communications 20060609 |
| Pharmacological therapy for acute respiratory distress syndrome. | Mayo Clinic proceedings 20060201 |
| Activation of the 12-lipoxygenase and signal transducer and activator of transcription pathway during neointima formation in a model of the metabolic syndrome. | American journal of physiology. Endocrinology and metabolism 20060101 |
| Survival methods, including those using competing risk analysis, are not appropriate for intensive care unit outcome studies. | Critical care (London, England) 20060101 |
| Bench-to-bedside review: the role of glycosaminoglycans in respiratory disease. | Critical care (London, England) 20060101 |
| Multidose streptozotocin induction of diabetes in BALB/c mice induces a dominant oxidative macrophage and a conversion of TH1 to TH2 phenotypes during disease progression. | Mediators of inflammation 20050831 |
| Use of liquid chromatography-tandem mass spectrometry for the analysis of pentoxifylline and lisofylline in plasma. | Biomedical chromatography : BMC 20050401 |
| Inflammatory blockade improves human pancreatic islet function and viability. | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20050301 |
| Lisofylline: a potential lead for the treatment of diabetes. | Biochemical pharmacology 20050101 |
| Pro/con clinical debate: It is acceptable to stop large multicentre randomized controlled trials at interim analysis for futility. Pro: Futility stopping can speed up the development of effective treatments. | Critical care (London, England) 20050101 |
| Pentoxifylline inhibits agonist-induced vasoconstriction in vascular smooth muscle and spontaneous peristalsis in isolated ileum. | Oncology research 20050101 |
| Inflammation blockade improves pancreatic islet function. | Transplantation proceedings 20041101 |
| Excess body weight is not independently associated with outcome in mechanically ventilated patients with acute lung injury. | Annals of internal medicine 20040302 |
| Lisofylline, a novel anti-inflammatory agent, enhances glucose-stimulated insulin secretion in vivo and in vitro: studies in prediabetic and normal rats. | Metabolism: clinical and experimental 20040301 |
| The novel anti-inflammatory agent lisofylline prevents autoimmune diabetic recurrence after islet transplantation. | Transplantation 20040115 |
| Lisofylline, a novel antiinflammatory compound, protects mesangial cells from hyperglycemia- and angiotensin II-mediated extracellular matrix deposition. | Endocrinology 20031201 |
| Emerging systemic pharmacologic approaches in acute respiratory distress syndrome. | Respiratory care clinics of North America 20031201 |
| Inhibition of STAT4 activation by lisofylline is associated with the protection of autoimmune diabetes. | Annals of the New York Academy of Sciences 20031101 |
| The novel anti-inflammatory compound, lisofylline, prevents diabetes in multiple low-dose streptozotocin-treated mice. | Pancreas 20030501 |
| The anti-inflammatory compound lisofylline prevents Type I diabetes in non-obese diabetic mice. | Diabetologia 20020901 |
| Developmental differences in the role of interleukins in hyperoxic lung injury in animal models. | Frontiers in bioscience : a journal and virtual library 20020701 |
| Lisofylline, a novel antiinflammatory agent, protects pancreatic beta-cells from proinflammatory cytokine damage by promoting mitochondrial metabolism. | Endocrinology 20020601 |
| Modulation of gastrointestinal wound repair and inflammation by phospholipids. | Biochimica et biophysica acta 20020523 |
| Specific therapies for inhalation injury. | Critical care medicine 20020301 |
| Effects of heparin and lisofylline on pulmonary function after smoke inhalation injury in an ovine model. | Critical care medicine 20020301 |
| Randomized, placebo-controlled trial of lisofylline for early treatment of acute lung injury and acute respiratory distress syndrome. | Critical care medicine 20020101 |
| Lisofylline: anti-acute respiratory distress syndrome or just anti-inflammatory? | Critical care medicine 20020101 |
| Lisofylline and lysophospholipids ameliorate experimental colitis in rats. | Digestion 20020101 |
| Understanding the roles of the transcription factors nuclear factor-kappaB and hypoxia-inducible factor-1alpha in lung injury. | Critical care (London, England) 20020101 |
| Science review: Redox and oxygen-sensitive transcription factors in the regulation of oxidant-mediated lung injury: role for nuclear factor-kappaB. | Critical care (London, England) 20020101 |
| Antioxidant and radical scavenging properties of 8-oxo derivatives of xanthine drugs pentoxifylline and lisofylline. | Biochemical and biophysical research communications 20011116 |
| Immunotherapy of inflammatory demyelinating diseases of the central nervous system. | Immunologic research 20010101 |
| CT-1501R selectively inhibits induced inflammatory monokines in human whole blood ex vivo. | Shock (Augusta, Ga.) 19940401 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.